Pharmacogenomic considerations in opioid analgesia

References

• FlockhartDASkaarTBerlinDSKleinTENguyenATClinically available pharmacogenomics testsClin Pharmacol Ther20098610911319369936
   PubMed Web of Science ®Google Scholar
• FruehFWAmurSMummaneniPPharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug usePharmacotherapy20082899299818657016
   PubMed Web of Science ®Google Scholar
• SimSCIngelman-SundbergMPharmacogenomic biomarkers: new tools in current and future drug therapyTrends Pharmacol Sci201132728121185092
   PubMed Web of Science ®Google Scholar
• RellingMVKleinTECPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research NetworkClin Pharmacol Ther20118946446721270786
   PubMed Web of Science ®Google Scholar
• JohnsonJAGongLWhirl-CarrilloMClinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosingClin Pharmacol Ther20119062562921900891
   PubMed Web of Science ®Google Scholar
• ScottSASangkuhlKGardnerEEClinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-452C19 (CYP2C19) genotype and clopidogrel therapyClin Pharmacol Ther20119032833221716271
   PubMed Web of Science ®Google Scholar
• RellingMVGardnerEESandbornWJClinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosingClin Pharmacol Ther20118938739121270794
   PubMed Web of Science ®Google Scholar
• CrewsKRGaedigkADunnenbergerHMClinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotypeClin Pharmacol Ther20129132132622205192
   PubMed Web of Science ®Google Scholar
• KehletHJensenTSWoolfCJPersistent postsurgical pain: risk factors and preventionLancet20063671618162516698416
   PubMed Web of Science ®Google Scholar
• CavallariLJeongHBressARole of cytochrome P450 genotype in the steps toward personalized drug therapyPharmgenomics Pers Med20114123136
   PubMedGoogle Scholar
• NielsenCSStaudRPriceDDIndividual differences in pain sensitivity: measurement, causation, and consequencesJ Pain20091023123719185545
   PubMed Web of Science ®Google Scholar
• SmithHSVariations in opioid responsivenessPain Physician20081123724818354715
   PubMed Web of Science ®Google Scholar
• AngstMSPhillipsNGDroverDROpioid pharmacogenomics using a twin study paradigm: methods and procedures for determining familial aggregation and heritabilityTwin Res Hum Genet20101341242520874462
   PubMed Web of Science ®Google Scholar
• NielsenCSStubhaugAPriceDDVassendOCzajkowskiNHarrisJRIndividual differences in pain sensitivity: genetic and environmental contributionsPain2008136212917692462
   PubMed Web of Science ®Google Scholar
• FoulkesTWoodJNPain genesPloS Genet20084e100008618654615
   PubMed Web of Science ®Google Scholar
• DiatchenkoLNackleyAGTchivilevaIEShabalinaSAMaixnerWGenetic architecture of human pain perceptionTrends Genet20072360561318023497
   PubMed Web of Science ®Google Scholar
• CoxJJReimannFNicholasAKAn SCN9A channelopathy causes congenital inability to experience painNature200644489489817167479
   PubMed Web of Science ®Google Scholar
• NilsenKBNicholasAKWoodsCGMellgrenSINebuchennykhMAaslyJTwo novel SCN9A mutations causing insensitivity to painPain200914315515819304393
   PubMed Web of Science ®Google Scholar
• GoldbergYPPriceNNamdariRTreatment of Na(v) 1.7-mediated pain in inherited erythromelalgia using a novel sodium channel blockerPain2012153808522035805
   PubMed Web of Science ®Google Scholar
• NguyenHNBregmanHBuchananJLDiscovery and optimization of aminopyrimidinones as potent and state-dependent Nav1.7 antagonistsBioorg Med Chem Lett2012221055106022209205
   PubMed Web of Science ®Google Scholar
• GoldbergYPMacFarlaneJMacDonaldMLLoss-of-function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populationsClin Genet20077131131917470132
   PubMed Web of Science ®Google Scholar
• FillingimRBKingCDRibeiro-DasilvaMCRahim-WilliamsBRileyJL3rdSex, gender, and pain: a review of recent clinical and experimental findingsJ Pain20091044748519411059
   PubMed Web of Science ®Google Scholar
• Ingelman-SundbergMSimSCGomezARodriguez-AntonaCInfluence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspectsPharmacol Ther200711649652618001838
   PubMed Web of Science ®Google Scholar
• EichelbaumMIngelman-SundbergMEvansWEPharmacogenomics and individualized drug therapyAnnu Rev Med20065711913716409140
   PubMed Web of Science ®Google Scholar
• WangBYangLPZhangXZHuangSQBartlamMZhouSFNew insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzymeDrug Metab Rev20094157364319645588
   PubMed Web of Science ®Google Scholar
• ZhouSFPolymorphism of human cytochrome P450 2D6 and its clinical significance: part IIClin Pharmacokinet20094876180419902987
   PubMed Web of Science ®Google Scholar
• DalyAKBrockmollerJBrolyFNomenclature for human CYP2D6 allelesPharmacogenetics199661932018807658
   PubMedGoogle Scholar
• StamerUMZhangLStuberFPersonalized therapy in pain management: where do we stand?Pharmacogenomics20101184386420504256
   PubMed Web of Science ®Google Scholar
• SistonenJSajantilaALaoOCoranderJBarbujaniGFuselliSCYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structurePharmacogenet Genomics2007179310117301689
   PubMed Web of Science ®Google Scholar
• GascheYDaaliYFathiMCodeine intoxication associated with ultrarapid CYP2D6 metabolismN Engl J Med20043512827283115625333
   PubMed Web of Science ®Google Scholar
• StamerUMStuberFMudersTMusshoffFRespiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplicationAnesth Analg200810792692918713907
   PubMed Web of Science ®Google Scholar
• MogilJSBaileyALSex and gender differences in pain and analgesiaProg Brain Res201018614115721094890
   PubMed Web of Science ®Google Scholar
• DoehringAKusenerNFluhrKNeddermeyerTJSchneiderGLotschJEffect sizes in experimental pain produced by gender, genetic variants and sensitization proceduresPloS One20116e1772421423693
   PubMed Web of Science ®Google Scholar
• PintoNDolanMEClinically relevant genetic variations in drug metabolizing enzymesCurr Drug Metab20111248749721453273
   PubMed Web of Science ®Google Scholar
• ThornCFKleinTEAltmanRBCodeine and morphine pathwayPharmacogenet Genomics20091955655819512957
   PubMed Web of Science ®Google Scholar
• LeePJDelaneyPKeoghJSleemanDShortenGDCatecholamine-o-methyltransferase polymorphisms are associated with postoperative pain intensityClin J Pain2011279310120842020
   PubMed Web of Science ®Google Scholar
• DerrySMooreRAMcQuayHJSingle dose oral codeine, as a single agent, for acute postoperative pain in adultsCochrane Database Syst Rev20104CD00809920393966
   PubMed Web of Science ®Google Scholar
• VanderVaartSBergerHSistonenJCYP2D6 polymorphisms and codeine analgesia in postpartum pain management: a pilot studyTher Drug Monit20113342543221743374
   PubMed Web of Science ®Google Scholar
• CiszkowskiCMadadiPPhillipsMSLauwersAEKorenGCodeine, ultrarapid-metabolism genotype, and postoperative deathN Engl J Med200936182782819692698
   PubMed Web of Science ®Google Scholar
• VoronovPPrzybyloHJJagannathanNApnea in a child after oral codeine: a genetic variant – an ultra-rapid metabolizerPaediatr Anaesth20071768468717564651
   PubMed Web of Science ®Google Scholar
• KorenGCairnsJChitayatDGaedigkALeederSJPharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed motherLancet200636870416920476
   PubMed Web of Science ®Google Scholar
• MenyRGNaumburgEGAlgerLSBrill-MillerJLBrownSCodeine and the breastfed neonateJ Hum Lact199392372408260056
   PubMedGoogle Scholar
• MadadiPKorenGCairnsJSafety of codeine during breast-feeding: fatal morphine poisoning in the breastfed neonate of a mother prescribed codeineCan Fam Physician200753333517872605
   PubMed Web of Science ®Google Scholar
• WillmannSEdgintonANCoboekenKAhrGLippertJRisk to the breast-fed neonate from codeine treatment to the mother: a quantitative mechanistic modeling studyClin Pharmacol Ther20098663464319710640
   PubMed Web of Science ®Google Scholar
• LotschJGeisslingerGA critical appraisal of human genotyping for pain therapyTrends Pharmacol Sci20103131231720483491
   PubMed Web of Science ®Google Scholar
• MadadiPRossCJHaydenMRPharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control studyClin Pharmacol Ther200985313518719619
   PubMed Web of Science ®Google Scholar
• MadadiPShiraziFWalterFGKorenGEstablishing causality of CNS depression in breastfed infants following maternal codeine usePaediatr Drugs20081039940418998750
   PubMedGoogle Scholar
• LotschJFluhrKNeddermayerTDoehringAGeisslingerGThe consequence of concomitantly present functional genetic variants for the identification of functional genotype-phenotype associations in painClin Pharmacol Ther200985253018548001
   PubMed Web of Science ®Google Scholar
• de LeonJSusceMTMurray-CarmichaelEThe AmpliChip CYP450 genotyping test: integrating a new clinical toolMol Diagn Ther20061013515116771600
   PubMed Web of Science ®Google Scholar
• LotschJRohrbacherMSchmidtHDoehringABrockmollerJGeisslingerGCan extremely low or high morphine formation from codeine be predicted prior to therapy initiation?Pain200914411912419395173
   PubMed Web of Science ®Google Scholar
• Wilder-SmithCHHufschmidEThormannWThe visceral and somatic antinociceptive effects of dihydrocodeine and its metabolite, dihydromorphine. A cross-over study with extensive and quinidine-induced poor metabolizersBr J Clin Pharmacol1998455755819663813
   PubMed Web of Science ®Google Scholar
• WebbJARostami-HodjeganAAbdul-ManapRHofmannUMikusGKamaliFContribution of dihydrocodeine and dihydro-morphine to analgesia following dihydrocodeine administration in man: a PK-PD modelling analysisBr J Clin Pharmacol200152354311453888
   PubMed Web of Science ®Google Scholar
• OttonSVSchadelMCheungSWKaplanHLBustoUESellersEMCYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphoneClin Pharmacol Ther1993544634727693389
   PubMed Web of Science ®Google Scholar
• HutchinsonMRMenelaouAFosterDJCollerJKSomogyiAACYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomesBr J Clin Pharmacol20045728729714998425
   PubMed Web of Science ®Google Scholar
• KaplanHLBustoUEBaylonGJInhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect abuse liabilityJ Pharmacol Exp Ther19972811031089103485
   PubMed Web of Science ®Google Scholar
• MadadiPHildebrandtDGongIYFatal hydrocodone overdose in a child: pharmacogenetics and drug interactionsPediatrics2010126e986e98920837591
   PubMed Web of Science ®Google Scholar
• GrondSSablotzkiAClinical pharmacology of tramadolClin Pharmacokinet20044387992315509185
   PubMed Web of Science ®Google Scholar
• EnggaardTPPoulsenLArendt-NielsenLBrosenKOssigJSindrupSHThe analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6Anesth Analg200610214615016368820
   PubMed Web of Science ®Google Scholar
• Garcia-QuetglasEAzanzaJRSadabaBMunozMJGilICampaneroMAPharmacokinetics of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotypePharmacol Res20075512213017175164
   PubMed Web of Science ®Google Scholar
• KirchheinerJKeulenJTBauerSRootsIBrockmollerJEffects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadolJ Clin Psychopharmacol200828788318204346
   PubMed Web of Science ®Google Scholar
• PedersenRSDamkierPBrosenKTramadol as a new probe for cytochrome P450 2D6 phenotyping: a population studyClin Pharmacol Ther20057745846715961977
   PubMed Web of Science ®Google Scholar
• PedersenRSDamkierPBrosenKEnantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizersEur J Clin Pharmacol20066251352116763825
   PubMed Web of Science ®Google Scholar
• StamerUMLehnenKHothkerFImpact of CYP2D6 genotype on postoperative tramadol analgesiaPain200310523123814499440
   PubMed Web of Science ®Google Scholar
• StamerUMMusshoffFKobilayMMadeaBHoeftAStuberFConcentrations of tramadol and O-desmethyl-tramadol enantiomers in different CYP2D6 genotypesClin Pharmacol Ther200782414717361124
   PubMed Web of Science ®Google Scholar
• WangGZhangHHeFFangXEffect of the CYP2D6*10 C188T polymorphism on postoperative tramadol analgesia in a Chinese populationEur J Clin Pharmacol20066292793116960721
   PubMed Web of Science ®Google Scholar
• EichhornABarthJChronic dizziness in a pain patient – pharmacogenomic identification of tramadol as cause [German]Rehabilitation (Stuttg)20104939339521140323
   PubMed Web of Science ®Google Scholar
• ElkalioubieAAllorgeDRobriquetLNear-fatal tramadol cardiotoxicity in a CYP2D6 ultrarapid metabolizerEur J Clin Pharmacol20116785585821691803
   PubMed Web of Science ®Google Scholar
• SalmanSSySKIlettKFPage-SharpMPaechMJPopulation pharmacokinetic modeling of tramadol and its O-desmethyl metabolite in plasma and breast milkEur J Clin Pharmacol20116789990821394525
   PubMed Web of Science ®Google Scholar
• IlettKFPaechMJPage-SharpMUse of a sparse sampling study design to assess transfer of tramadol and its O-desmethyl metabolite into transitional breast milkBr J Clin Pharmacol20086566166618294329
   PubMed Web of Science ®Google Scholar
• TzvetkovMVSaadatmandARLotschJTegederIStinglJCBrockmollerJGenetically polymorphic OCT1: another piece in the puzzle of the variable pharmacokinetics and pharmacodynamics of the opioidergic drug tramadolClin Pharmacol Ther20119014315021562485
   PubMed Web of Science ®Google Scholar
• LehtonenPStenTAitioOGlucuronidation of racemic O-desmethyl-tramadol, the active metabolite of tramadolEur J Pharm Sci20104152353020797434
   PubMed Web of Science ®Google Scholar
• OlkkolaKTHagelbergNMOxycodone: new “old” drugCurr Opin Anaesthesiol20092245946219369865
   PubMed Web of Science ®Google Scholar
• LalovicBKharaschEHofferCRislerLLiu-ChenLYShenDDPharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolitesClin Pharmacol Ther20067946147916678548
   PubMed Web of Science ®Google Scholar
• SamerCFDaaliYWagnerMThe effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodoneBr J Pharmacol201016090791820590587
   PubMed Web of Science ®Google Scholar
• GronlundJSaariTIHagelbergNMNeuvonenPJLaineKOlkkolaKTEffect of inhibition of cytochrome P450 enzymes 2D6 and 3A4 on the pharmacokinetics of intravenous oxycodone: a randomized, three-phase, crossover, placebo-controlled studyClin Drug Investig201131143153
   Web of Science ®Google Scholar
• GronlundJSaariTIHagelbergNMNeuvonenPJOlkkolaKTLaineKExposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 aloneBr J Clin Pharmacol201070788720642550
   PubMed Web of Science ®Google Scholar
• KummerOHammannFMoserCSchallerODreweJKrahenbuhlSEffect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodoneEur J Clin Pharmacol201167637120857093
   PubMed Web of Science ®Google Scholar
• LiukasAHagelbergNMKuusniemiKNeuvonenPJOlkkolaKTInhibition of cytochrome P450 3A by clarithromycin uniformly affects the pharmacokinetics and pharmacodynamics of oxycodone in young and elderly volunteersJ Clin Psychopharmacol20113130230821508859
   PubMed Web of Science ®Google Scholar
• NieminenTHHagelbergNMSaariTIOxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavirEur J Clin Pharmacol20106697798520697700
   PubMed Web of Science ®Google Scholar
• NieminenTHHagelbergNMSaariTIRifampin greatly reduces the plasma concentrations of intravenous and oral oxycodoneAnesthesiology20091101371137819417618
   PubMed Web of Science ®Google Scholar
• GronlundJSaariTHagelbergNEffect of telithromycin on the pharmacokinetics and pharmacodynamics of oral oxycodoneJ Clin Pharmacol20105010110819755414
   PubMed Web of Science ®Google Scholar
• GronlundJSaariTIHagelbergNNeuvonenPJOlkkolaKTLaineKMiconazole oral gel increases exposure to oral oxycodone by inhibition of CYP2D6 and CYP3A4Antimicrob Agents Chemother2011551063106721173180
   PubMed Web of Science ®Google Scholar
• HagelbergNMNieminenTHSaariTIVoriconazole drastically increases exposure to oral oxycodoneEur J Clin Pharmacol20096526327118836708
   PubMed Web of Science ®Google Scholar
• HagelbergNMNieminenTHSaariTIInteraction of oxycodone and voriconazole – a case series of patients with cancer pain supports the findings of randomised controlled studies with healthy subjectsEur J Clin Pharmacol20116786386421221959
   PubMed Web of Science ®Google Scholar
• NieminenTHHagelbergNMSaariTISt John’s wort greatly reduces the concentrations of oral oxycodoneEur J Pain20101485485920106684
   PubMed Web of Science ®Google Scholar
• SaariTIGronlundJHagelbergNMEffects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodoneEur J Clin Pharmacol20106638739720076952
   PubMed Web of Science ®Google Scholar
• NieminenTHHagelbergNMSaariTIGrapefruit juice enhances the exposure to oral oxycodoneBasic Clin Pharmacol Toxicol201010778278820406214
   PubMed Web of Science ®Google Scholar
• LembergKKSiiskonenAOKontinenVKYli-KauhaluomaJTKalsoEAPharmacological characterization of noroxymorphone as a new opioid for spinal analgesiaAnesth Analg200810646347018227301
   PubMed Web of Science ®Google Scholar
• MaddocksISomogyiAAbbottFHayballPParkerDAttenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodoneJ Pain Symptom Manage1996121821898803381
   PubMed Web of Science ®Google Scholar
• HeiskanenTOlkkolaKTKalsoEEffects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodoneClin Pharmacol Ther1998646036119871425
   PubMed Web of Science ®Google Scholar
• SusceMTMurray-CarmichaelEde LeonJResponse to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizerProg Neuropsychopharmacol Biol Psychiatry2006301356135816631290
   PubMed Web of Science ®Google Scholar
• SamerCFDaaliYWagnerMGenetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safetyBr J Pharmacol201016091993020590588
   PubMed Web of Science ®Google Scholar
• ZwislerSTEnggaardTPNoehr-JensenLThe hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphismBasic Clin Pharmacol Toxicol200910433534419281600
   PubMed Web of Science ®Google Scholar
• ZwislerSTEnggaardTPMikkelsenSBrosenKSindrupSHImpact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesiaActa Anaesthesiol Scand20105423224019719813
   PubMed Web of Science ®Google Scholar
• AndreassenTNEftedalIKlepstadPDo CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre studyEur J Clin Pharmacol201268556421735164
   PubMed Web of Science ®Google Scholar
• FareedACasarellaJAmarRVayalapalliSDrexlerKMethadone maintenance dosing guideline for opioid dependence, a literature reviewJ Addict Dis20102911420390694
   PubMed Web of Science ®Google Scholar
• ShaiovaLBergerABlindermanCDConsensus guideline on parenteral methadone use in pain and palliative carePalliat Support Care2008616517618501052
   PubMedGoogle Scholar
• FredheimOMMoksnesKBorchgrevinkPCKaasaSDaleOClinical pharmacology of methadone for painActa Anaesthesiol Scand20085287988918331375
   PubMed Web of Science ®Google Scholar
• AnsermotNAlbayrakOSchlapferJSubstitution of (R,S)-methadone by (R)-methadone: impact on QTc intervalArch Intern Med201017052953620308640
   PubMedGoogle Scholar
• QuigleyCOpioid switching to improve pain relief and drug tolerabilityCochrane Database Syst Rev20043CD00484715266542
   PubMedGoogle Scholar
• CollerJKJoergensenCFosterDJLack of influence of CYP2D6 genotype on the clearance of (R)-, (S)- and racemic-methadoneInt J Clin Pharmacol Ther20074541041717725248
   PubMed Web of Science ®Google Scholar
• CrettolSDeglonJJBessonJABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatmentClin Pharmacol Ther20068066868117178267
   PubMed Web of Science ®Google Scholar
• FonsecaFde la TorreRDiazLContribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and responsePloS One20116e1952721589866
   PubMed Web of Science ®Google Scholar
• ShiranMRLennardMSIqbalMZContribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatmentBr J Clin Pharmacol200967293719133059
   PubMed Web of Science ®Google Scholar
• CollerJKBarrattDTDahlenKLoennechenMHSomogyiAAABCB1 genetic variability and methadone dosage requirements in opioid-dependent individualsClin Pharmacol Ther20068068269017178268
   PubMed Web of Science ®Google Scholar
• LevranOO”HaraKPelesEABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependenceHum Mol Genet2008172219222718424454
   PubMed Web of Science ®Google Scholar
• BuntenHLiangWJPounderDSeneviratneCOsseltonMDCYP2B6 and OPRM1 gene variations predict methadone-related deathsAddict Biol20111614214421158011
   PubMed Web of Science ®Google Scholar
• BuntenHLiangWJPounderDJSeneviratneCOsseltonDOPRM1 and CYP2B6 gene variants as risk factors in methadone-related deathsClin Pharmacol Ther20108838338920668445
   PubMed Web of Science ®Google Scholar
• LevranOPelesEHamonSRandesiMAdelsonMKreekMJCYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addictionAddict Biol Epub July 25, 2011
   Web of Science ®Google Scholar
• WangSCHoIKTsouHHCYP2B6 polymorphisms influence the plasma concentration and clearance of the methadone S-enantiomerJ Clin Psychopharmacol20113146346921694616
   PubMed Web of Science ®Google Scholar
• LandauRCahanaASmileyRMAntonarakisSEBlouinJLGenetic variability of mu-opioid receptor in an obstetric populationAnesthesiology20041001030103315087647
   PubMed Web of Science ®Google Scholar
• TanECTanCHKarupathivanUYapEPMu opioid receptor gene polymorphisms and heroin dependence in Asian populationsNeuroreport20031456957212657887
   PubMed Web of Science ®Google Scholar
• CrowleyJJOslinDWPatkarAAA genetic association study of the mu opioid receptor and severe opioid dependencePsychiatr Genet20031316917312960749
   PubMed Web of Science ®Google Scholar
• KroslakTLaforgeKSGianottiRJHoANielsenDAKreekMJThe single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptorJ Neurochem2007103778717877633
   PubMed Web of Science ®Google Scholar
• BondCLaForgeKSTianMSingle-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addictionProc Natl Acad Sci U S A199895960896139689128
   PubMed Web of Science ®Google Scholar
• ZhangYWangDJohnsonADPappACSadeeWAllelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118GJ Biol Chem2005280326183262416046395
   PubMed Web of Science ®Google Scholar
• BeyerAKochTSchroderHSchulzSHolltVEffect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptorJ Neurochem20048955356015086512
   PubMed Web of Science ®Google Scholar
• OertelBGKettnerMScholichKA common human micro-opioid receptor genetic variant diminishes the receptor signaling efficacy in brain regions processing the sensory information of painJ Biol Chem20092846530653519116204
   PubMed Web of Science ®Google Scholar
• MahmoudSThorsellASommerWHPharmacological consequence of the A118G mu opioid receptor polymorphism on morphine- and fentanyl-mediated modulation of Ca(2) channels in humanized mouse sensory neuronsAnesthesiology20111151054106221926562
   PubMed Web of Science ®Google Scholar
• FillingimRBKaplanLStaudRThe A118G single nucleotide polymorphism of the mu-opioid receptor gene (OPRM1) is associated with pressure pain sensitivity in humansJ Pain2005615916715772909
   PubMed Web of Science ®Google Scholar
• HuangCJLiuHFSuNYAssociation between human opioid receptor genes polymorphisms and pressure pain sensitivity in femalesAnaesthesia2008631288129519032295
   PubMed Web of Science ®Google Scholar
• VossenHKenisGRuttenBvan OsJHermensHLousbergRThe genetic influence on the cortical processing of experimental pain and the moderating effect of pain statusPloS One20105e1364121049025
   PubMed Web of Science ®Google Scholar
• ZwislerSTEnggaardTPNoehr-JensenLThe antinociceptive effect and adverse drug reactions of oxycodone in human experimental pain in relation to genetic variations in the OPRM1 and ABCB1 genesFundam Clin Pharmacol20102451752419845769
   PubMed Web of Science ®Google Scholar
• LandauRKernCColumbMOSmileyRMBlouinJLGenetic variability of the mu-opioid receptor influences intrathecal fentanyl analgesia requirements in laboring womenPain200813951418403122
   PubMed Web of Science ®Google Scholar
• WongCAMcCarthyRJBlouinJLandauRObservational study of the effect of mu-opioid receptor genetic polymorphism on intrathecal opioid labor analgesia and post-cesarean delivery analgesiaInt J Obstet Anesth20101924625320171873
   PubMed Web of Science ®Google Scholar
• CamorciaMCapognaGStirparoSBerrittaCBlouinJLLandauREffect of mu-opioid receptor A118G polymorphism on the ED50 of epidural sufentanil for labor analgesiaInt J Obstet Anesth201221404422153130
   PubMed Web of Science ®Google Scholar
• SiaATLimYLimECA118G single nucleotide polymorphism of human mu-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesiaAnesthesiology200810952052618719451
   PubMed Web of Science ®Google Scholar
• TanECLimYTeoYYGohRLawHYSiaATEthnic differences in pain perception and patient-controlled analgesia usage for postoperative painJ Pain2008984985518550441
   PubMed Web of Science ®Google Scholar
• TanECLimECTeoYYLimYLawHYSiaATEthnicity and OPRM variant independently predict pain perception and patient-controlled analgesia usage for post-operative painMol Pain200953219545447
   PubMed Web of Science ®Google Scholar
• LandauROne size does not fit all: genetic variability of mu-opioid receptor and postoperative morphine consumptionAnesthesiology200610523523716871054
   PubMed Web of Science ®Google Scholar
• LandauROrtnerCCarvalhoBChallenges in interpreting joined allelic combinations of OPRM1 and COMT genesAnesth Analg201111343221788333
   PubMed Web of Science ®Google Scholar
• ChouWYWangCHLiuPHLiuCCTsengCCJawanBHuman opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomyAnesthesiology200610533433716871067
   PubMed Web of Science ®Google Scholar
• ChouWYYangLCLuHFAssociation of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplastyActa Anaesthesiol Scand20065078779216879459
   PubMed Web of Science ®Google Scholar
• CoulbaultLBeaussierMVerstuyftCEnvironmental and genetic factors associated with morphine response in the postoperative periodClin Pharmacol Ther20067931632416580900
   PubMed Web of Science ®Google Scholar
• KolesnikovYGabovitsBLevinAVoikoEVeskeACombined catechol-O-methyltransferase and mu-opioid receptor gene polymorphisms affect morphine postoperative analgesia and central side effectsAnesth Analg201111244845321127283
   PubMed Web of Science ®Google Scholar
• ZhangWChangYZKanQCAssociation of human micro-opioid receptor gene polymorphism A118G with fentanyl analgesia consumption in Chinese gynaecological patientsAnaesthesia20106513013520003118
   PubMed Web of Science ®Google Scholar
• FukudaKHayashidaMIkedaKKoukitaYIchinoheTKanekoYDiversity of opioid requirements for postoperative pain control following oral surgery – is it affected by polymorphism of the mu-opioid receptor?Anesth Prog20105714514921174568
   PubMedGoogle Scholar
• FukudaKHayashidaMIdeSAssociation between OPRM1 gene polymorphisms and fentanyl sensitivity in patients undergoing painful cosmetic surgeryPain200914719420119783098
   PubMed Web of Science ®Google Scholar
• WuWDWangYFangYMZhouHYPolymorphism of the micro-opioid receptor gene (OPRM1 118 A > G) affects fentanyl-induced analgesia during anesthesia and recoveryMol Diagn Ther20091333133719791836
   PubMed Web of Science ®Google Scholar
• ZhangWYuanJJKanQCZhangLRChangYZWangZYStudy of the OPRM1 A118G genetic polymorphism associated with postoperative nausea and vomiting induced by fentanyl intravenous analgesiaMinerva Anestesiol201177333921150856
   PubMed Web of Science ®Google Scholar
• GinosarYDavidsonEMMerozYBlotnickSShachamMCaracoYMu-opioid receptor (A118G) single-nucleotide polymorphism affects alfentanil requirements for extracorporeal shock wave lithotripsy: a pharmacokinetic-pharmacodynamic studyBr J Anaesth200910342042719605407
   PubMed Web of Science ®Google Scholar
• KlepstadPRakvagTTKaasaSThe 118 A > G polymorphism in the human mu–opioid receptor gene may increase morphine requirements in patients with pain caused by malignant diseaseActa Anaesthesiol Scand2004481232123915504181
   PubMed Web of Science ®Google Scholar
• CampaDGioiaATomeiAPoliPBaraleRAssociation of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain reliefClin Pharmacol Ther20088355956617898703
   PubMed Web of Science ®Google Scholar
• Reyes-GibbyCCSheteSRakvagTExploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT genePain2007130253017156920
   PubMed Web of Science ®Google Scholar
• KlepstadPFladvadTSkorpenFInfluence from genetic variability on opioid use for cancer pain: a European genetic association study of 2294 cancer pain patientsPain20111521139114521398039
   PubMed Web of Science ®Google Scholar
• LotschJvon HentigNFreynhagenRCross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centersPharmacogenet Genomics20091942943619514130
   PubMed Web of Science ®Google Scholar
• BelferISegallSCOMT genetic variants and painDrugs Today (Barc)20114745746721695287
   PubMed Web of Science ®Google Scholar
• HickeyOTNugentNFBurkeSMHafeezPMudrakouskiALShortenGDPersistent pain after mastectomy with reconstructionJ Clin Anesth20112348248821911195
   PubMed Web of Science ®Google Scholar
• JensenKBLonsdorfTBSchallingMKosekEIngvarMIncreased sensitivity to thermal pain following a single opiate dose is influenced by the COMT val(158)met polymorphismPloS One20094e601619547755
   PubMed Web of Science ®Google Scholar
• SteinDJNewmanTKSavitzJRamesarRWarriors versus worriers: the role of COMT gene variantsCNS Spectr20061174574817008817
   PubMed Web of Science ®Google Scholar
• DiatchenkoLNackleyAGSladeGDCatechol-O-methyltransferase gene polymorphisms are associated with multiple pain-evoking stimuliPain200612521622416837133
   PubMed Web of Science ®Google Scholar
• ZubietaJKHeitzegMMSmithYRCOMT val158 met genotype affects mu-opioid neurotransmitter responses to a pain stressorScience20032991240124312595695
   PubMed Web of Science ®Google Scholar
• AndersenSSkorpenFVariation in the COMT gene: implications for pain perception and pain treatmentPharmacogenomics20091066968419374521
   PubMed Web of Science ®Google Scholar
• NackleyAGTanKSFechoKFloodPDiatchenkoLMaixnerWCatechol-O-methyltransferase inhibition increases pain sensitivity through activation of both beta2- and beta3-adrenergic receptorsPain200712819920817084978
   PubMed Web of Science ®Google Scholar
• TchivilevaIELimPFSmithSBEffect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot studyPharmacogenet Genomics20102023924820216107
   PubMed Web of Science ®Google Scholar
• LoggiaMLJensenKGollubRLWasanADEdwardsRRKongJThe catechol-O-methyltransferase (COMT) val158 met polymorphism affects brain responses to repeated painful stimuliPloS One20116e2776422132136
   PubMed Web of Science ®Google Scholar
• WalterCLotschJMeta-analysis of the relevance of the OPRM1 118A > G genetic variant for pain treatmentPain200914627027519683391
   PubMed Web of Science ®Google Scholar
• KimHClarkDDionneRAGenetic contributions to clinical pain and analgesia: avoiding pitfalls in genetic researchJ Pain20091066369319559388
   PubMed Web of Science ®Google Scholar
• KimHRamsayELeeHWahlSDionneRAGenome-wide association study of acute post-surgical pain in humansPharmacogenomics20091017117919207018
   PubMed Web of Science ®Google Scholar
• WolfeDWechuckJKriskyDMataMFinkDJA clinical trial of gene therapy for chronic painPain Med2009101325133019818042
   PubMed Web of Science ®Google Scholar
• GloriosoJCFinkDJGene therapy for pain: introduction to the special issueGene Ther20091645345419357693
   PubMed Web of Science ®Google Scholar
• FinkDJWechuckJMataMGene therapy for pain: results of a phase I clinical trialAnn Neurol20117020721221796661
   PubMed Web of Science ®Google Scholar